Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

This study has been completed.
Information provided by (Responsible Party):
Eisai Inc. Identifier:
First received: August 1, 2011
Last updated: May 13, 2016
Last verified: May 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2015
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):